GlassScriptPhysician profile
Saroj B Sharma
NPI 1003927062
$4,872.18
in general payments reported to CMS, 2019-2025
32 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $458 · 2021: $1,104 · 2022: $608 · 2023: $905 · 2024: $971 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,264.33 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $724.31 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $500.40 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $275.27 | 2020-2025 | |
| Amgen INC. | $273.17 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $238.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.04 | 2019-2024 | Jardiance |
| Dexcom, INC. | $214.62 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.68 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $150.09 | 2020-2021 | |
| Glaxosmithkline, LLC. | $146.49 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Eisai INC. | $97.24 | 2020-2021 | |
| Axsome Therapeutics, INC. | $65.91 | 2023 | Sunosi |
| Idorsia Pharmaceuticals US INC | $57.89 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $52.77 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.02 | 2020-2021 | |
| Lundbeck LLC | $43.56 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $35.53 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.41 | 2019 | |
| Vital Connect, INC | $30.36 | 2024 | Vitalpatch Rtm |
| Abbott Laboratories | $30.29 | 2025 | |
| Horizon Therapeutics Plc | $29.59 | 2021 | |
| Sanofi Pasteur INC. | $27.14 | 2020-2021 | |
| Bausch Health US, LLC | $24.90 | 2020 | |
| Scilex Pharmaceuticals INC. | $23.28 | 2024 | |
| Ucb, INC. | $19.71 | 2025 | Rystiggo |
| Organogenesis INC. | $18.63 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.83 | 2021 | |
| Merck Sharp & Dohme LLC | $14.60 | 2019 | |
| Currax Pharmaceuticals LLC | $13.44 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.81 | 2025 | Voquezna |
| Allergan, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saroj Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.